NEW YORK— The Veterans Affairs New York Harbor Healthcare System (VA NYHHS) has started a study using the Daxor BVA-100 Blood Volume Analyzer to guide fluid therapy for patients undergoing renal dialysis.
Medical instrumentation company Daxor said it received a signed trial agreement from the VA NY Harbor Healthcare System, Manhattan campus, in July. This agreement will provide the VA NY with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of cardiac conditions and have been associated with poor prognosis.
The VA NYHHS is part of the Southern New York/New Jersey Veterans Integrated Service Network, one of 23 such networks serving the healthcare needs of veteran populations across the country.
The New York Campus of the VA NYHHS has been designated the referral center for all invasive cardiovascular procedures in VSN3. The hospital's HIV/AIDS and Dialysis Programs have been designated as Veterans Health Administration (VHA) Centers of Excellence.
"We are very excited to utilize this instrument in our Dialysis Study and are looking forward to the data that the BVA-100 will provide to us in helping to guide therapy," said Dr. David Goldfarb, Clinical Chief of Nephrology.
